Short Interest in Exicure, Inc. (NASDAQ:XCUR) Increases By 24.2%

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 28,200 shares, a growth of 24.2% from the February 13th total of 22,700 shares. Based on an average daily trading volume, of 106,200 shares, the short-interest ratio is presently 0.3 days. Currently, 7.4% of the shares of the stock are short sold.

Exicure Stock Performance

NASDAQ XCUR opened at $12.40 on Wednesday. The company has a market capitalization of $32.31 million, a P/E ratio of -5.99 and a beta of 3.84. The company has a fifty day moving average of $10.34 and a 200-day moving average of $9.39. Exicure has a 52-week low of $1.44 and a 52-week high of $36.00.

Exicure (NASDAQ:XCUR) last issued its earnings results on Tuesday, March 18th. The company reported ($3.39) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Exicure

An institutional investor recently bought a new position in Exicure stock. Geode Capital Management LLC bought a new position in Exicure, Inc. (NASDAQ:XCUR) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 12,645 shares of the company’s stock, valued at approximately $173,000. Geode Capital Management LLC owned 0.48% of Exicure as of its most recent SEC filing. 42.82% of the stock is currently owned by institutional investors.

About Exicure

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.